First Online: 3 September 2015
: C.M.M. has served as a consultant for Novartis, Merck and Valeant, has received research contracts from Novartis and Merck, and research grants from the National Institute of Mental Health and the Canadian Institutes of Health Research. C.L.D. has received grants and/or research support from the US NIH, IntelClinic, Merck, Pernix and Teva. He has also served as a consultant for Jazz, Teva and Merck. A.D.K. has received grants and/or research support from the NIH, Teva, Eisai, Sunovion, NeoSync, Brainsway, Janssen, ANS St. Jude and Novartis. He has also served as a consultant for Abbott, Astellas, AstraZeneca, Attentiv, Bristol-Myers Squibb, Teva, Eisai, Eli Lilly, Jazz, Janssen, Merck, Neurocrine, Novartis, Otsuka, Palladin, Pernix, Pfizer, Lundbeck, Roche, Somnus, Sunovion, Somaxon and Vantia. D.R. has served as a consultant for AbbVie. He is also a board member of the Freiburg Educational Institute for Behavioural Therapy (a non-profit institution) and receives honoraria for teaching and supervising psychologists in training to become certified psychotherapists. A.G.H., R.M. and K.S. declare no competing interests.